medigraphic.com
ISSN 0185-6014 (Impreso)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2009, Número 2

<< Anterior Siguiente >>

Rev Mex Patol Clin Med Lab 2009; 56 (2)


Cáncer cervicouterino: ¿Qué papel etiológico juega la infección con el virus del papiloma humano?

Barba EJR

Idioma: Español
Referencias bibliográficas: 127
Paginas: 83-104
Archivo PDF: 265.65 Kb.


RESUMEN

Debido a que el cáncer cervicouterino (CaCu) es la segunda causa de muerte en mujeres alrededor del mundo y como una medida tomada por los sistemas públicos de salud con el afán de disminuir esta incidencia anual, sobre todo en lo que respecta a mujeres que habitan en países en vías de desarrollo, los tamizajes masivos mediante la realización de la prueba de Papanicolaou son una buena opción para tal fin. Por otra parte, existe una vasta información publicada mundialmente acerca de la estrecha relación que guarda este incremento anual de cáncer cervicouterino con el incremento en la incidencia de infecciones genitales por el virus del papiloma humano (VPH), sobre todo de los tipos considerados de alto riesgo, sin que exista evidencia contundente que demuestre esta causa-efecto. En el presente artículo se revisan aspectos importantes acerca del virus del papiloma humano y su estrecha relación con el desarrollo de cáncer cervicouterino.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Fontham ET. Infectious diseases and global cancer control. CA Cancer J Clin 2009; 59: 5-7.

  2. Winer E, Gralow J, Diller L, Karlan B, Loehrer P, Pierce L, Demetri G et al. Clinical cancer advances 2008: Major research advances in cancer treatment, prevention, and screening. A report from the American Society of Clinical Oncology. J Clin Oncol 2008; 7: 812-826.

  3. Tyring Stephen. Introduction: Perspectives on human papillomavirus infection. Am J Med 1997; 102 (5A):1-2.

  4. D´Souza G, Sugar E, Ruby W, Gravitt P, Gillison M. Analysis of the effect of DNA purification on detection of human papillomavirus in oral rinse sample by PCR. J Clin Microbiol 2005; 43 (11): 5526-5535.

  5. Strome SE, Savva A, Brissett AE, Gostout BS, Lewis J, Clayton AC, McGovern R et al. Squamous cell carcinoma of the tonsils: A molecular analysis of HPV Associations. Clin Cancer Res 2002; 8: 1093-1100.

  6. DM Parkin. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006; 118 (12): 303-304.

  7. Rodríguez FM, Lunar T, Lara MGM, López GY. Calidad en la toma de muestra para la detección oportuna de cáncer cervicouterino. Rev Mex Patol Clin 2006; 53 (4): 229-234.

  8. Mahdavi Ali, J Monk Bradley. Vaccines against human papillomavirus and cervical cancer: Promises and challenges. Oncologist 2005; 10: 528-538.

  9. Siraj Sami, Naseruddin Höti, Han-Mei Xu, Zilong Shen, Xiaofeng Huang. Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo. J Biochem 2008; 144: 357-362.

  10. Castle PE, Solomon D, Schiffman M, Wheeler CM. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 2005; 97: 1066-1071.

  11. Achtar MS, Ibrahim R, Herrin VE, Gause B, Steinberg S, Grollman F, Rahma O et al. Pre-immature dendritic cells pulsed with human papillomavirus 16 E7 peptide vaccine in advanced cervical cancer. Vaccine 2009; 27 (5):701-707.

  12. Ben-Bassat H, Rosenbaum-Mitrani S, Hartzstark Z, Levitzki R, Chaouat M, Shlomai Z, Klein BY et al. Typhostins that suppress the growth of human papilloma virus 16-immortalized human keratinocytes. J Pharmacol Exper Therap 1999; 290 (3): 1442-1457.

  13. Toshiyuki Sasagawa, Walid Basha, Hiroshi Yamazaki, Masaki Inoue. High-risk and multiple human papillomavirus infections associated with cervical abnormalities in japanese women. Cancer Epidemiol Biomark Prevent 2001; 10: 45-52.

  14. Garland ZM. Cancer screening. Can we really beat cervical cancer? MJA 2003; 178 (12): 647-650.

  15. Smith KL, Tristram A, Gallagher KM, Fiander AN, Man E. Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18. Inter Immuno 2004; 17 (2): 167-176.

  16. Evans M, Borysiewicz LK, Evans AS, Rowe M, Jones M, Gileadi U, Cerundolo V, Man E. Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J Immunol 2001, 167: 5420-5428.

  17. Snijders PJ, Van den Brule AJ, Meijer CJ. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol 2003; 201 (1): 1-6.

  18. Münger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, Grace M, KyungWon Huh. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 2004; 78 (21): 11451-11460.

  19. Beutner KR, Tyring S. Human papillomavirus and human disease. Am J Med 1997; 102 (5A): 9-15.

  20. C. Pirog E, Kleter B, Olgac Semra, Bobkiewicz P, Lindeman J, G V Quint Wim, M Richart R, Isacson C. prevalence of humanpapillomavirus DNA in different histological subtypes of cervical adenocarcinoma. Am J Pathol 2000; 157: 1055-1062.

  21. Chen R, Sehr P, Zaterboer T, Leivo I, Pawlita M, Vaheri, Leena-Maija Aaltonen. Presence of DNA of human papillomavirus 16 but no other types in tumor-free tonsillar tissue. J Clin Microbiol 2005: 43 (3): 1408-1410.

  22. Pérez SM, Leonard Feliu Ibrahín, Alvarez, Amores I, Domínguez C, González N, Paniagua M, Quintero CS, Bienvenido G. Infección por papillomavirus (PVH) en carcinomas colorrectales. Rev Panam Infectol 2004; 6 (3): 26-33.

  23. Aldrich T, Landis S, García SG, Becker D, Sanhueza P, Higuera A. Cervical cancer and the HPV link: Identifying areas for education in Mexico City‘s public hospitals. Sal Pub Mex 2006; 48: 236-243.

  24. Harald zur Hausen. Papillomavirus and cancer: From basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-350.

  25. Schiffman MH, Castle P. Epidemiologic studies of a necessary causal risk factor: Human papillomavirus infection and cervical neoplasia. J Nation Cancer Inst 2003; 95 (6): E2.

  26. Muñoz N, Bosch F X, De Sanjosé S, Herrero R, Castellsague X, Shah Keerti V, Snidjers PJF, Meijer Chris JLM. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-527.

  27. Lajous M, Mueller N, Cruz VC, Aguilar LV, Franceschi S, Hernández AM, Lazcano PE. Determinants of prevalence, acquisition, and persistence of human papillomavirus in healthy mexican military men. Cancer Epidemiol Biomark Prev 2005; 14 (7): 1710-1716.

  28. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102 (5A): 3-8.

  29. Hsiu-Ting T, Ching-Hu W, Hsiao-Ling L, Ruei-Nian L, Yi-Ching T, Hung-Yi C, Trong-Neng W et al. Association between quantitative high-risk human papillomavirus DNA load and cervical intraepithelial neoplasm risk. Cancer Epidemiol Biomark Prev 2005; 14 (11): 2544-2549.

  30. Calleja MI, Villa LL, Prado JC, Kalantari M, Bruce A, Williamson AL, Chung Lap-Ping, Collins RJ et al. Worldwide genomic diversity of the high-risk human papillomavirus types 31, 35, 52 and 58, four close relatives of human papillomavirus type 16. J Virol 2005; 79: 13630-13640.

  31. Jian H, Swan DC, Smith SJ, Lum SH, Sefers SE, Unger ER, Yi-Wei T. Simultaneous amplification and identification of 25 human papillomavirus types with Templex Technology. J Clin Microbiol 2006; 44 (11): 4157-4162.

  32. Söderlund SA, Dillner J, Carlson J. High-troughput genotyping of oncogenic human papilloma viruses with MALDI-TOF Mass Spectrometry. Clin Chem 2008; 54 (1): 86-92.

  33. Maucort BD, Franceschi S, Plummer M. IARC HPV Prevalence surveys study group. International correlation between human papillomavirus prevalence and cervical cancer incidence. Cancer Epidemiol Biomark Prev 2008; 17 (3): 717-720.

  34. Castle PE, Porras P, Quint WG, Rodríguez AC, Schiffman M, Gravitt PE, González P et al. Comparison of two PCR-Based Human Papillomavirus Genotyping Methods. J Clin Microbiol 2008; 46 (10): 3437-3445.

  35. Muñoz N, Bosch X, De Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJF, Meijer CJLM. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-527.

  36. Clifford JM, Rana RK, Franceschi S, Smith JS, Gerald Gough, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: Comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomark Prev 2005; 14 (5): 1157-1164.

  37. Calleja MIE, Kalantari M, Allan B, Williamson AL, Lap-Ping Chung, Collins RJ, Zuna RE et al. Papillomavirus subtypes are natural and old taxa: phylogeny of human papillomavirus types 44 and 55 and 68a and –b. J Virol 2005; 79 (10): 6565-6569.

  38. Brown C, Kowalczyk AM, Taylor ER, Morgan IM, Gaston K. p53 represses human papillomavirus type 16 DNA replication via the viral E2 protein. Virol J 2008; 5: 5-13.

  39. Feeney KM, Parish JL. Targeting mitotic chromosomes: a conserved mechanism to ensure viral genome persistence. Proceedings of The Royal Society Biological Sciences 2009. Rspb.royalsocietypublishing.org.

  40. Abbate EA, Berger JM, Botchan MR. The X-ray structure of the papillomavirus helicase in complex with its molecular matchmaker E2. Genes Develop 2004; 18: 1981-1996.

  41. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci 2006; 110: 525-541.

  42. H zur Hausen. Papillomaviruses in human cancers. Proc Assoc Am Physicians 1999; 111 (6): 581-587.

  43. Swan DC, Rajeevan M, Tortolero LG, Follen M, Tucker RA, Unger ER. Human papillomavirus type 16 E2 and E6/E7 variants. Gynecol Oncol 2005; 96 (3): 695-700.

  44. Munday JS, Hanlon EM, Howe L, Squires RA, French AF. Feline cutaneous viral papilloma associated with human papillomavirus type 9. Vet Pathol 2007; 44: 924-927.

  45. Pérez SM, Ibrahín L, Amores SI, Domínguez C, González N, Paniagua M, Quintero S, Bienvenido G. Virus del papiloma humano. Actualización y presentación de un caso de carcinoma esofágico asociado a VPH. Rev Mex Patol Clin 2003; 50 (1):12-19.

  46. Bishop B, Dasgupta J, Chen XS. Structure-based engineering of papillomavirus major capside L1: Controlling particle assembly. Virol J 2007; 4 (3): 1-6.

  47. Geipert N. Vaccinating men for HPV: New strategy for preventing cervical cancer in women? J Nation Cancer Inst 2005; 97 (9): 630-631.

  48. Balsitis S, Dick F, Dyson N, Lambert PF. Critical roles for Non-pRb targets of human papillomavirus type 16 E7 in cervical carcinogenesis. Cancer Res 2006; 66 (19): 9393-9400.

  49. De la Rosa JP, Monroy GA, Mora GML, Reynaga PCG, Hernandez MJ, Weisss Steider B, Gomez LMA. An HPV 16 L1-based chimeric human papillomavirus-like particles containing a string of epitopes produced in plants i sable to elicit humoral and cytotoxic T-cell activity in mice. Virol J 2009: 6 (2): 6-12.

  50. D´Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944-1956.

  51. Schwartz SM, Daling JR, Doody DR, Wipf GC, Carter JJ, Madeleine MM, Er-Jia Mao et al. Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst 1998; 90: 1626-1636.

  52. Zimmerman JM, Maher III JL. Solution measurement of DNA curvature in papillomavirus E2 binding sites. Nucleic Acids Research 2003; 31 (17): 5134-5139.

  53. Thomas JT, Oh ST, Terhune SS, Laimins LA. Cellular changes induced by low-risk human papillomavirus type 11 in keratinocytes that stably maintain viral episomes. J Virol 2001; 75 (16): 7564-7571.

  54. Lavergne D, De Villiers EM. Papillomavirus in esophageal papillomas and carcinomas. Int J Cancer 1999; 80 (5): 681-684.

  55. Chang F, Syrjanen S, Shen Q, Clintorino M, Santopietro R, Tosi P, Syrjanen K. Human papillomavius involvement in esophageal carcinogenesis in the high-incidence areas of China. A study of 700 cases by screening and type-specific in situ hybridization. Scand J Gastroenterol 2000; 35 (2): 123-130.

  56. Kreimer AR, Alberg AJ, Daniel R, Gravitt PE, Viscidi R, Garrett ES, Shah KV, Gillison ML. Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis 2004; 189 (4): 686-698.

  57. Smith EM, Hoffman HT, Summersgill KS, Kirchner HL, Turek LP, Haugen TH. Human papillomavirus and risk of oral cancer. Laryngoscope 1998;108 (7): 1098-1103.

  58. Summersgill KF, Smith EM, Levy BT, Allen JM, Haugen TH, Turek LP. Human papillomavirus in the oral cavities of children and adolescents. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 91 (1): 62-69.

  59. Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervical papillomavirus infection in young women. N Engl J Med 1998; 338: 423-428.

  60. Butsch Kovacic M, Castle PE, Herrero R, Sciffman M, Sherman ME, Wacholder S et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res 2006; 66 (20): 10112-10119.

  61. Palefsky JM, Holly EA, Gonzalez J, Berline J, Ahn DK, Greenspan JS. Detection of human papillomavirus DNA in anal intraepithelial neoplasia and anal cancer. Cancer Res 1991; 51: 1014-1019.

  62. Trottier H, Mahmud S, Costa MC, SobrinhoJP, Duarte FE, Rohan TE et al. Human papillomavirus infections with multiple types and risk cervical neoplasia. Cancer Epidemiol Biomark Prevent 2006; 15 (7): 1274-1280.

  63. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis. Br J Cancer 2003; 88 (1):63-73.

  64. Quint WGV, Pagliusi SR, Lelie N, De Villiers EM, Wheeler CM. The World Health Organization Human Papillomavirus DNA International Collaborative Study Group. Results of the First World Health Organization International Collaborative Study of Detection of Human Papillomavirus DNA. J Clin Microbiol 2006; 44 (2): 571-579.

  65. N. Sanjib Banerjee, Genovese NJ, Noya F, Wei-Ming Chien, Broker TR, Chow LT. Conditionally activated E7 proteins of high-risk and low-risk human papillomaviruses induce S phase in postmitotic, differentiated human keratinocytes. J Virol 2006; 80 (13): 6517-6524.

  66. Dell G, Gaston K. Human papillomaviruses and their role in cervical cancer. Cell Mol Life Sci 2001; 58(889): 1923-1942.

  67. Ferrera A, VelemaJP, Figueroa M, Bulnes R, Toro LA, Claros JM, Odessa de Barahona, Melchers WJG. Co-factors related to the causal relationship between human papillomavirus and invasive cervical cáncer in Honduras. International J Epidemiol 2000; 29: 817-825.

  68. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000; 92: 1500-1510.

  69. Durante AJ, Williams AB, Da Costa M, Darragh TM, Khoshnood K, Palefsky JM. Incidence of anal cytological abnormalities in a cohort of human immunodeficiency virus-infected women. Cancer Epidemiol Biomark Prevent 2003; 12: 638-642.

  70. Bosch FX, Lorincz v, Muñoz N, Meijer CJM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 0-21.

  71. Block SL, Nolan T, Sattler C, Barr EE, Giacoletti KED, Marchant CD et al. Reisinger. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (Types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118: 2135-2145.

  72. Draganov P, Todorov S, Karchev T, Kalvatchev Z. Identification of HPV DNA in patients with juvenile-onset recurrent respiratory papillomatosis using SYBR Green real-time PCR. Int J Pediatr Otorhinolaryngol 2006; 70 (3): 469-473.

  73. http://es.wikipedia.org/wiki/Virus_del_papiloma _humano.

  74. Appleby P, Beral V, Berrington GA, Colin D, Franceschi S, Goodhill A, Green J et al. International collaboration of epidemiological of cervical cancer. Cervical cancer and hormonal contraceptives: Collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007; 370 (9599): 1609-1621.

  75. Ogston P, Raj K, Beard P. Productive replication of adeno-associated virus can occur in human papillomavirus type 16 (HPV-16) Episome-containing keratinocytes and is augmented by the HPV-16 E2 Protein. J Virol 2000; 74 (8): 3494-3504.

  76. Krüger KS, Munk C, Falck FW, Ole Jorgensen H, Meijer CJLM, Van der Brule AJC. Acquisition and persistence of human papillomavirus infection in younger men: A prospective follow-up study among danish soldiers. Cancer Epidemiol Biomark Prevent 2005; 14 (6): 1528-1533.

  77. Burk R, Kelly P, Feldman J, Bromberg J, Vermund S, Dehovitz J, Landesman S. Declining prevalence of cervical human papillomavirus infection with age is independent of other risk factors. Sex Trans Dis 1996; 23 (4): 333-341.

  78. Thomas JT, Oh ST, Terhune SS, Laimins LA. Cellular changes induced by low-risk human papillomavirus type 11 in keratinocytes that stably maintain viral episomes. J Virol 2001; 75 (16): 7564-7571.

  79. Orjuela M, Ponce CV, Ridaura C, Lecona E, Leal C, Abramson DH, Orlow I et al. Presence of human papillomavirus in tumor tissue from children with retinoblastoma: An alternative mechanism for tumor development. Clin Cancer Res 2000; 6: 4010-4016.

  80. Ndisang D, Vishwaine Budhram-Mahadeo, Latchman DS. The Brn-3a transcription factor plays a critical role in regulating human papilloma virus gene expression and determining the growth characteristics of cervical cancer cells. J Biol Chem 1999; 274 (40): 28521-28527.

  81. Eiben GL, Velders MP, Schreiber H, Cassetti MC, Pullen JK, Smith LR, Kast WM. Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice. Cancer Res 2002; 62: 5792-5799.

  82. Fakruddin JM, Lempcicki RA, Gorelick RJ, Jun Yang , Adelsberger JW, Garcia PAJ, Pinto LA et al. Noninfectious papilloma virus-Like particles inhibit HIV-1 replication; implications for immune control of HIV-1 infection by IL-27. Blood 2007; 109: 1841-1849.

  83. Da Silva DM, Fausch SC, Verbeek JS, Kast WM. Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcg receptors and contributes to acquisition of T cell immunity. J Immunol 2007; 178: 7587-7597.

  84. De la Cruz HE, Pérez CE, Contreras PA, Cantú D, Alejandro Mohar, Lizano M, Dueñas GA. The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study. Virol J 2007; 4: 18-29.

  85. Reelfs O, yao-Zhong Xu, Massey A, Karran P, Storey A. Thiothymidine plus low-dose UVA kills hyperproliferative human skin cells independently of their human papilloma virus status. Mol Cancer Ther 2007; 6 (9): 2487-2495.

  86. Genther Williams M, Disbrow GL, Schlegel R, Daekee Lee, Threadgill DW, Lambert PF. Requirement of epidermal growth factor receptor for hyperplasia induced by E5, a high-risk human papillomavirus oncogene. Cancer Res 2005; 65 (15): 6534-6542.

  87. Smith EM, Ritchie JM, Summersgill KF, Hoffman, Dong Hong Wang, Haugen TH, Turek LP. Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst 2004; 96: 449-455.

  88. Flores ER, Allen HBL, Lee D, Lambert PF. The human papillomavirus type 16 E7 oncogene is required for the productive stage of the viral life cycle. J Virol 2000; 74 (14): 6622-6631.

  89. Bruno S, Fabbi M, Tiso M, Santamaria B, Ghiotto F, Saverino D, Tenca C et al. Cell activation via CD44 occurs in advanced stages of squamous cell carcinogenesis. Carcinogenesis 2000; 21 (5): 893-900.

  90. Gao Q, Kumar A, Singh L, Huibregtse JM, Beaudenon S, Srinivasan S, Wazer DE et al. Papillomavirus E6-induced degradation of E6TP1 is mediated by E6AP ubiquitin ligase. Cancer Res 2002; 62: 3315-3321.

  91. Tyagi A, Singh RP, Agarwal C, Agarwal R. Silibinin activates p53-caspase 2 pathway and causes caspase-mediated cleavage of Cip1/p21 in apoptosis induction in bladder transitional-cell papilloma RT4r cells: Evidence for a regulatory loop between p53 and caspase 2. Carcinogenesis 2006; 27 (11): 2269-2280.

  92. Collins LL, Din-Lii Lin, Xiau-Min Mu, Chawnshang Chang. Feedback regulation between orphan nuclear receptor TR2 and human papilloma virus type 16. J Biol Chem 2001; 276 (29): 27316-27321.

  93. Jong-Sung Park, Boyer S, Mitchell K, Gilfor D, Birrer M, Darlington G, Wafik El Deiry et al. Expressin of human papilloma virus E7 protein causes apoptosis and inhibits DNA synthesis in primary hepatocytes via increased expression of p21Cip-1/WAF1/MDA6*. J Biol Chem 2000; 275 (1): 18-28.

  94. McLaughlin DME, Bromberg WJL, Meyers C. The role of the human papillomavirus type 18 E7 oncoprotein during the complete viral life cycle. Virology 2005; 338 (1): 61-68.

  95. Araujo AK, Marques CA, Mendes CS, Lina VL, Boccardo E, Pérez MG, Pérez AI et al. Production of human papillomavirus type 16 L1 virus-like particles by recombinant lactobacillus casei cells. Appl Environ Microbiol 2006; 72 (1): 745-752.

  96. Shwu-Yuan Wu, A-Young Lee, Hou SY, Kemper J, Erdjument BH, Tempst P, Cheng-Ming Chiang. Brd4 links chromatin targeting to HPV transcriptional silencing. Genes Develop 2006; 20: 2383-2396.

  97. Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, Schneider A, Adams M et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical Cancer. Clin Cancer Res 2002; 8: 3676-3685.

  98. Blachon E, Bellanger S, Demeret C, Thierry F. Nucleo-cytoplasmic shuttling of high risk human papillomavirus E2 proteins induces apoptosis. J Biol Chem 2005; 280 (43): 36088-36098.

  99. Gunn GR, Zubair A, Peters C, Zhen-Kun Pan, Tzyy-Choou Wu, Paterson Y. Two listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 2001; 167: 6471-6479.

  100. Shishinn Sun, Steinberg BM. PTEN is a negative regulator of STAT3 activation in human papillomavirus-infected cells. J Gen Virol 2002; 83: 1651-1658.

  101. Mendoza JA, Jacob Y, Cassonnet P, Favre M. Human papillomavirus type 5 E6 oncoprotein represses the transforming growth factor b signaling pathway by binding to SMAD3. J Virol 2006; 80 (24): 12420-12424.

  102. Musheng Zeng, Ajay Kumar, Gaoyuan Meng, Qingshen Gao, Goberdhan Dimri, David Wazer, Hamid Band, Vimla Band. Human papilloma virus 16 E6 oncoprotein inhibits retinoic X receptor-mediated transactivation by targeting human ADA3 coactivator. J Biol Chem 2002; 277 (47): 45611-45618.

  103. Smith EM, Donghong W, Rubenstein LM, Morris WA. Association between p53 and human papillomavirus in head and neck cancer survival. Cancer Epidemiol Biomark Prevent 2008; 17 (2): 421-427.

  104. Schiffman M, Wheeler CM, Castle PE. Atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion triage study group. Human papillomavirus DNA remains detectable longer than cervical cytologic abnormalities. J Infect Dis 2002; 186 (8):1169-1172.

  105. Genovese NJ, Banerjee NS, Broker TR, Chow LT. Casein kinase II motif-dependent phosphorylation of human papillomavirus E7 protein promotes p130 degradation ans s.phase induction in differentiated human keratinocytes. J Virol 2008; 82 (10): 4862-4873.

  106. Trofatter KF. Diagnosis of human papillomavirus genital tract infection. Am J Med 1997; 102 (5A): 21-27.

  107. Mork J, Lie AK, Eystein G, Göran H, Egil J, Pentti K, Bjorn M et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001; 344 (15): 1125-1131.

  108. Leen-Jan van Doorn, Molijn A, Kleter B, Quint W, Colau B. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbial 2006; 44 (9): 3292-3298.

  109. Davies P, Kornegay J, Iftner T. Current methods of testing for human papillomavirus. Best Pract Res Clin Obstet Gynaecol 2001; 15 (5): 677-700.

  110. Slee EA, O‘Connor DJ, Xin L. To die or not to die: How does p53 decide? Oncogene 2004; 23: 2809-2818.

  111. Jochen vom Brocke, Schmeiser HH, Reinbold M, Hollstein M. MEF immortalization to investigate the ins and outs of mutagenesis. Carcinogenesis 2006; 27 (11): 2141-2147.

  112. Slebos RJC, Yajun Y, Ely K, Carter J, Evjen A, Xueqiong Z, Yu S et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res 2006; 12 (3):701-709.

  113. Pintos J, Franco EL, Black MJ, Bergeron J, Arella. Human papillomavirus and prognoses of patients with cancers of the upper aerodigestive tract. Cancer 1999; 85 (9): 1903-1909.

  114. Ritchie JM, Smith EM, Summersgill KF, Hoffman HT, Wang D, Klussmann JP, Turek LP et al. Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Ints J Cancer 2003; 104 (3): 336-344.

  115. Leachman SA, Tigelaar RE, Shlyankevich M, Slade MD,Irwin M, Chang E, Wu TC et al. Granulocyte-macrophage colony-stimulating factor priming plus papillomavirus E6 DNA vaccination: Effects on papilloma formation and regression in the coottontail rabbit papillomavirus-rabbit model. J Virol 2000; 74 (18): 8700-8708.

  116. Kaiyo Takubo, Naotaka Shimomura-Izumiyama, Hidemi Koiwai, Naoko Honma, Yukiyoshi Esaqki, Tomomi Yoshida, Takashi Nakajima et al. Detection of human papillomavirus infection of the cervix in very elderly women using PCR. Clin cancer Res 2005; 11 (8): 2919-2923.

  117. Sufang Wu, Li Meng, Shixuan Wang, Wei Wang, Ling Xi, Xun Tian, Gang Chen et al. Reversal of the malignant phenotype of cervical cancer caski cells through adeno-associated virus – mediated delivery of HPV16 E7 antisense RNA. Clin Cancer Res 2006; 12 (7): 2032-2037.

  118. Edwards S, Carne C. Oral sex and the transmission of viral STIs. Sex Transm Inf 1998; 74: 6-10.

  119. Mattiussi S, Kazue Matsumot5o, Illi B, Martelli F, Copogrossi MC, Gaetano C. Papilloma protein E6 abrogates shear stress-dependent survival in human endothelial cells: Evidence for specialized functions of paxillin. Cardio Res 2006; 70: 578-588.

  120. Woodruff RA, Bonde RK, Bonilla JA, Romero CH. Molecular identification of a papilloma virus from coetaneous lesions of captive and free-ranging florida manatees. J Wildlife Dis 2005; 41 (2): 437-441.

  121. Leen-Jan van Doorn, Quint W, Kleter B, Molijn A, Colau B, Martin MT, Kravang-In et al. Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF10 line probe assay. J Clin Microbiol 2002; 40 (3): 979-983.

  122. Rajeevan MS, Swan DC, Nisenbaum R, Lee DR, Vernon SD, Ruffin MT, Horowitz IR et al. Epidemiologic and viral factors associated with cervical neoplasia in HPV-16-positive women. Inst J Cancer 2005; 115 (1): 114-120.

  123. Sun CA, Lai HC, Chang CC, Neih S, Yu CP, Chu TY. The significance of human papillomavirus viral load in prediction of histologic severity and size of squamous intraepithelial lesions of uterine cervix. Gynecol Oncol 2001; 83 (1): 95-99.

  124. Bosch FX, Munoz N. The viral etiology of cervical cancer. Virus Res 2002; 89 (2): 183-190.

  125. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, Duarte FE et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001: 286 (24): 3106-3114.

  126. Melnikow J, Birch S. Human papillomavirus triage of atypical squamous cells of undetermined significance: Cost-effective, but at what cost? J Natl Cancer Inst 2006; 98 (2): 82-83.

  127. Ronco G, Segnan N, Giorgi-RP, Zappa M, Casadei GP, Carozzi, Dalla Palma P et al. Human papillomavirus testing and liquid-based cytology: Results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst 2006: 98: 765-774.




2020     |     www.medigraphic.com